Oryzon participates as Sponsor of both the CureSHANK’s 2nd Annual Phelan-McDermid Syndrome Drug Development Symposium, aimed at the scientific community, which will be held June 26-27; and the ...

Drew Denmark, 16, is one of 3,600 people diagnosed Phelan Mcdermid Syndrome, which is a genetic condition caused by the deletion of chromosome 22 or the mutation of the SHANK3 gene.

Phelan-McDermid Syndrome (PMS) is a rare neurodevelopmental disorder caused by deletions or mutations in the terminal region of chromosome 22, most often affecting the SHANK3 gene.

Phelan-McDermid Syndrome (PMS) is a rare neurodevelopmental disorder caused by deletions or mutations in the terminal region of chromosome 22, most often affecting the SHANK3 gene.

SHANK3 haploinsufficiency causes Phelan-McDermid syndrome (also known as 22q13.3 deletion syndrome), a rare genetic disorder with an estimated prevalence of 1 in 10,000. 1,2 Genetic sequencing ...

The Food and Drug Administration (FDA) has granted Orphan Drug designation to BA-102 for the treatment of Phelan-McDermid syndrome, a rare neurodevelopmental disorder linked to autism.

A DODWORTH toddler’s rare condition - which affects just a handful of people in the country - will be at the centr... Local ...

Mitchell finally got an answer in November 2014, when Alexa was 13. A geneticist diagnosed Phelan-McDermid syndrome, a rare genetic disorder caused by a missing or structural change of chromosome 22.

Phelan-McDermid Syndrome (PMS) is a rare neurodevelopmental disorder caused by deletions or mutations in the terminal region of chromosome 22, most often affecting the SHANK3 gene.

Oryzon participates as Sponsor of both the CureSHANK’s 2nd Annual Phelan-McDermid Syndrome Drug Development Symposium, aimed at the scientific community, which will be held June 26-27; and the ...

Phelan-McDermid Syndrome (PMS) is a rare neurodevelopmental disorder caused by deletions or mutations in the terminal region of chromosome 22, most often affecting the SHANK3 gene.

MADRID and CAMBRIDGE, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics ...